In
HIV and ID Observations, Dr. Paul Sax highlights the good news coming out of this PANORAMIC trial.
Infectious diseases specialists responded lukewarmly to a preliminary analysis from PANORAMIC, a U.K. study that looked at molnupiravir as early treatment for adults with COVID-19 who were at increased risk of adverse outcomes. In the latest HIV and ID Observations, Dr. Paul Sax acknowledges the important concerns about both the study and the drug but points out that it's also worth highlighting the good news coming out of this trial.
Do you want to be notified whenever Dr. Sax posts? Sign up to receive notifications by email by using the Subscribe box.
Want to see more from NEJM Journal Watch? Register here.